Evidence map›Paper›PMID 39546606›Full record

ArticleScience advances2024

Mechanotransduction governs CD40 function and underlies X-linked hyper-IgM syndrome.

Hyun-Kyu Choi, Stefano Travaglino, Matthias Münchhalfen, Richard Görg, Zhe Zhong, Jintian Lyu, David M Reyes-Aguilar, Jürgen Wienands, Ankur Singh, Cheng Zhu

Abstract read
In one paragraph

Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Case Report:Frontiers in immunology · 2025
    Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Hyun-Kyu ChoiWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332, USA.ORCID 0000-0001-9192-891X
Stefano TravaglinoWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332, USA.ORCID 0000-0002-7362-2527
Matthias MünchhalfenInstitute of Cellular and Molecular Immunology, University Medical Center Göttingen, 13 Göttingen, Germany.ORCID 0000-0002-9240-9342
Richard GörgInstitute of Cellular and Molecular Immunology, University Medical Center Göttingen, 13 Göttingen, Germany.ORCID 0000-0003-4513-8698
Zhe ZhongWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332, USA.ORCID 0009-0001-8659-3040
Jintian LyuWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332, USA.
David M Reyes-AguilarWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332, USA.ORCID 0009-0006-0426-526X
Jürgen WienandsInstitute of Cellular and Molecular Immunology, University Medical Center Göttingen, 13 Göttingen, Germany.ORCID 0000-0001-8278-7668
Ankur SinghWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332, USA.ORCID 0000-0002-3501-2277
Cheng ZhuWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332, USA.ORCID 0000-0002-1718-565X

Funding

Exploiting the Mechanobiology of PD-1 for Cancer ImmunotherapyU01CA250040 · NCI · GEORGIA INSTITUTE OF TECHNOLOGY · PI ZHU, CHENG · 2020 to 2024
$3.5M
Hydrogel-based Organoids of African-American Lymphomas to Study B Cell Receptor Pathway InhibitorsR01CA266052 · NCI · GEORGIA INSTITUTE OF TECHNOLOGY · PI JEAN L KOFF, Ankur Singh · 2022 to 2026
$2.7M
Lymphoid Experimental Therapeutics Platform to Study Cooperative Signaling inHuman LymphomasR01CA238745 · NCI · GEORGIA INSTITUTE OF TECHNOLOGY · PI SINGH, ANKUR · 2020 to 2024
$2.2M
Dysregulated mechanoimmunology of epigenetics-driven lymphomasU01CA280984 · NCI · GEORGIA INSTITUTE OF TECHNOLOGY · PI Ankur Singh, Cheng Zhu · 2023 to 2026
$2.1M
NCI NIH HHS R01 CA238745NCI NIH HHS R01 CA266052NCI NIH HHS U01 CA250040NCI NIH HHS U01 CA280984
6 · The paper itself

Abstract

B cell maturation depends on cognate interactions between the T and B cells. Upon interaction with CD40 ligand (CD40L) on T cells, CD40 delivers costimulatory signals alongside B cell antigen receptor (BCR) signaling to regulate affinity maturation and antibody class switch. Mutations affecting CD40-CD40L interactions cause abnormal antibody responses in immunodeficiencies known as X-linked hyper-IgM syndrome (X-HIgM). Here, we study the CD40-mediated mechanotransduction in B cells, which likely occurs during their physical contacts with T cells. We found that CD40 forms catch bond with CD40L that lasts longer at larger forces, both B and T cells exert tension on CD40-CD40L bonds, and force enhances CD40 signaling and antibody class switch. X-HIgM CD40L mutations impair catch bond formation, suppress endogenous tension, and reduce force-enhanced CD40 signaling, leading to deficiencies in antibody class switch. Our findings highlight the role of mechanotransduction in CD40 function and provide insights into the mechanisms underlying X-HIgM syndrome.

Indexed as

B-LymphocytesCD40 AntigensCD40 LigandHyper-IgM Immunodeficiency Syndrome, Type 1Mechanotransduction, CellularAnimalsHumansMiceMutationSignal TransductionT-LymphocytesCD40 AntigensCD40 Ligand

Identifiers

PMID39546606
PMCPMC11566996

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.